RxDoctor Payments Data

Mergime Imeri, PA

Physician Assistant · Grand Rapids, MINPI 1215649025

Payments from drug & device makers

$2,123in general payments, 2019–2025

Across 68 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$671
  • Xeris Pharmaceuticals, Inc.$477
  • Medtronic$186
  • Sequel Med Tech, LLC$175
  • Novo Nordisk$174
  • BETA Bionics, Inc.$138
  • plus $303 from 5 others

What the payments were for

  • Food & beverage$2,123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,123 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$15,540
Medicare patients
103
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$126,161
JardianceEmpagliflozin43$58,113
TrulicityDulaglutide17$29,752
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$21,575
Humalog Kwikpen U-100Insulin Lispro48$14,416
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$10,731
HumalogInsulin Lispro13$9,469
Novolog FlexpenInsulin Aspart11$1,933
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$1,212
LantusInsulin Glargine,hum.Rec.Anlog13$1,204
Pioglitazone Hcl23$560
Metformin Hcl23$352
Metformin Hcl ErMetformin Hcl16$168
Lisinopril13$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$62$165,381118 claims
Boehringer IngelheimJardiance$671$58,11343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →